Clinical molecular diagnostics and biomarker discoveries are constantly advancing in conjunction with an increasing number of therapeutics. Different biomarker technologies exist depending on the availability of the biological samples. Data interpretation of comprehensive genomic profiling is essential for individualized treatment. Currently, customized treatment for patients defines the standard of care. The genomic landscape of cancers is better defined. The first two courses of biomarkers in molecular and immuno-oncology were a great success with more than 20 international speakers from 6 countries, 200 participants from Lebanon and the region.